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Proton  magnetic  resonance  spectroscopy  (1H-MRS)  has  been  widely  applied  in  human  studies.  There  is
now  a  large  literature  describing  ﬁndings  of brain  MRS  studies  with  mental  disorder  patients  including
schizophrenia,  bipolar  disorder,  major  depressive  disorder,  and  anxiety  disorders.  However,  the ﬁndings
are  mixed  and  cannot  be  reconciled  by any  of the  existing  interpretations.  Here  we proposed  the  new  the-
ory  of  neuron-glia  integrity  to  explain  the  ﬁndings  of  brain 1H-MRS  stuies.  It proposed  the neurochemical
correlates  of neuron-astrocyte  integrity  and  axon-myelin  integrity  on the  basis  of  update  of  neurobiolog-
ical  knowledge  about  neuron-glia  communication  and  of  experimental  MRS  evidence  for  impairments  ineuron-glia integrity
RS
eurometabolites
eurodegenerative disorders
sychiatric disorders
neuron-glia  integrity  from the  authors  and  the  other  investigators.  Following  the  neuron-glia  integrity
theories,  this  review  collected  evidence  showing  that glutamate/glutamine  change  is a good  marker  for
impaired neuron-astrocyte  integrity  and  that changes  in  N-acetylaspartate  and  lipid  precursors  reﬂect
impaired  myelination.  Moreover,  this  new  theory  enables  us  to explain  the  differences  between  MRS
ﬁndings  in  neuropsychiatric  and  neurodegenerative  disorders.
© 2016  The  Authors.  Published  by  Elsevier  Ltd. This  is an  open  access  article  under  the CC  BY-NC-ND
license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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messenger molecules (Reuss and Unsicker, 1998). Upon the gap
junctions, the calcium wave propagates from astrocyte to astrocyte
as described in the following. First, neuronal glutamate activates
Fig. 1. Scheme of the tripartite synapse. Carton representing the transfer of informa-References  . .  . . . .  . . .  .  . . . .  . . . .  . . . .  .  . . .  .  . .  .  . . .  . . . .  . . .  . . . . .  . . .  .  . . .  . . .  . . . .  . 
. Introduction
Proton magnetic resonance spectroscopy (1H-MRS) is evolved
rom the nuclear magnetic resonance spectroscopy in chemistry
o determine the structure of molecules (Allen, 1990). One of the
ajor motivations for using 1H MRS  is the greater sensitivity of the
H, compared with either 31P or 13C. This feature translates into
elative sensitivities of about 10:1 relative to 31P and about 64:1
elative to 13C at equal concentrations of compounds and isotopic
nrichments (Rosen and Lenkinski, 2007). Therefore, 1H MRS  uses
he same hardware as standard magnetic resonance imaging (MRI),
hereas observing nuclei other than 1H requires the development
f radio frequency (RF) coils and other specialized hardware tuned
o their speciﬁc frequencies.
1H-MRS has been sucessfully applied in the research of many
rain disorders. Since the early 1990s, the non-invasive measure-
ent of brain metabolite concentrations with 1H MRS  has provided
 unique avenue for extending our understanding of the pathogen-
sis of neuropsychiatric disorders. There is now a large literature
escribing the ﬁndings of brain MRS  studies in the major psychiatric
isorders including schizophrenia, bipolar disorder (BD), major
epressive disorder (MDD), and anxiety disorders. However, there
s a great deal of inconsistency across ﬁndings from most of studies
ith mental disorders. Although discrepancies in methodologies
pplied in individual studies can partially explain the inconsistent
ndings, the main reason is due to the complexity of psychiatric
isorders. Therefore, interpreting the mixed ﬁndings necessitates a
ew insight to or understanding of neurobiology behind the altered
rain metabolites detected by 1H MRS. The present review provided
 neurobiological background of glia cells with a focus on neuron-
lia contacts and introduced the neurochemical proﬁle detected by
H MRS  in the brain. Then, it proposed the neurochemical corre-
ates of neuron-astrocyte integrity and axon-myelin integrity on
he basis of update of neurobiological knowledge about neuron-
lia communication and experimental evidence for impairments in
euron-glia integrity from the authors and the other investigators.
ollowing this theory, it reviewed a great body of 1H MRS  studies
hat measured brain metabolites in patients with schizophrenia,
D, or MDD  patients. Finally, it commented on the differences
etween MRS  ﬁndings in neuropsychiatric and neurodegenerative
isorders.
. Glia cells and neuron-glia contacts
.1. Astrocytes and their contacts with blood vessels and neurons
Astrocytes are the most abundant cells in the brain. The
ame derives from the ‘star-like’ shape of one kind of these
ells–protoplasmic astrocytes which contain bundles of an abun-
ant ﬁlamentous component of the cytoskeleton, the glial ﬁbrillary
cidic protein (Pereira and Furlan, 2010). The protoplasmic astro-
ytes mainly locate in the gray matter of the brain whereas ﬁbrous
strocytes reside in the white matter. Individual astrocyte can con- .  . .  . . . .  . . .  . . . . .  .  . . . . .  . .  .  .  . . .  . . .  . . . . . . .  .  . . .  .  . . . .  .  .  . . . . .  . . . . . . .  .  .  .  . . .  .  . .  . . . .  .  574
tact with and ensheath thousands of synapses between neurons.
This close spatial relationship has led to the term tripartite synapse
(Fig. 1). In this neuron-astrocyte contact, astrocytes respond to
pre-synaptic input by means of calcium waves and releasing
gliotransmitters that modulate neuronal activity and synaptic
plasticity. Brieﬂy, the neurotransmitter released by neurons acti-
vates calcium-based signaling cascades in astrocytes which in turn
release neuroactive substances that signal back to neurons. The dif-
ferent types of molecules secreted by astrocytes can either inhibit
or enhance overall levels of neuronal activity (Allen and Barres,
2009).
Astrocytes participating in tripartite synapses are coupled by
gap junctions forming a network that can support large-scale
integrative functions of the brain, from dynamic glucose delivery
(Rouach et al., 2008) to cognitive information processing (Perea and
Araque, 2005; Robertson, 2002). The gap junctions are composed
of connexins, which are channel-forming proteins and assem-
ble astrocytes into functional syncytia permitting exchange of
small molecules including metabolites, catabolites, and secondtion between neuronal elements and astrocyte at the tripartite synapse. Astrocytes
respond with Ca2+ elevation to neurotransmitters (Nt) released during synaptic
activity and, in turn, control neuronal excitability and synaptic transmission through
the Ca2+-dependent release of gliotransmitters (Gt). Figure was reproduced from
Perea et al. with authorization of the publisher.
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Fig. 2. The propagation of the calcium wave from astrocyte to astrocyte via gap
junctions (small blue rectangles). The activation of one astrocyte, by means of the
binding of neuronal glutamate with a metabotropic receptor activating the inositol
triphosphate (IP3) pathway, releases calcium ions from the endoplasmatic reticu-
lum, forming calcium waves that propagate in the syncytium. Figure was reproducedH. Xu et al. / Neuroscience and Bio
n astrocyte by binding with a metabotropic receptor and activat-
ng the inositol triphosphate pathway, then the astrocyte releases
alcium ions from the endoplasmatic reticulum, forming calcium
aves that propagate in the syncytium (Pereira and Furlan, 2010)
Fig. 2). Besides the astrocyte somata, astrocyte processes trans-
embrane entry of calcium ions generates 30–40% of the ions
levations (Srinivasan et al., 2015).
In addition to altering neuronal information processing,
alcium-evoked release of messengers from astrocytes was  sug-
ested to regulate the energy supply to the brain neurons in
hree important ways (Bazargani and Attwell, 2016). For space
imit, described here is the ﬁrst way in which astrocytes form the
euro-vascular connection with brain capillaries through astroglial
erivascular processes (Oberheim et al., 2009). The neurovascu-
ar unit integrates neural circuitry with local blood ﬂow. By this
ay, astrocyte acts as a bridge between vasculature and brain
arenchyma and establishes a functional link between neural
ctivity and local blood ﬂow. Increase in local neuronal activity
nduces astroglial Ca2+ signals that in turn trigger release of vasoac-
ive substances from the end-foot thus regulating the local blood
ow (Iadecola and Nedergaard, 2007; Metea and Newman, 2006;
ulligan and MacVicar, 2004; Takano et al., 2006; Zonta et al.,
003). It is important to point out that the calcium ions rises in
strocyte somata may  be too slow to generate rapid blood ﬂow
ncreases (Nizar et al., 2013; Schulz et al., 2012; Schummers et al.,
008). In constrast, the calcium ions transients in astrocyte pro-
esses are relatively faster (Tang et al., 2015) and occur before or
ith a similar time course to the increase of blood ﬂow (Lind et al.,
013; Nimmerjahn et al., 2009; Otsu et al., 2015). Furthermore,
strocytes provide metabolic support to neurons localized in their
erritorial domains through a glucose-lactate shuttle. Increase in
euronal activity leads to inﬂux of Na+ into astrocyte thus increas-
ng the cytosolic Na+ concentration which in turn stimulates lactate
ynthesis through glycolysis. The lactate subsequently is trans-
orted to neurons, where it is converted to pyruvate to produce the
ell’s energy molecule adenosine triphosphate (ATP) (Magistretti,
006, 2009).
In summary, astrocytes regulate synaptic transmission between
eurons as the third part of the tripartite synapse. Astrocytes com-
unicate each other through waves of calcium ions propagating
nformation over large distances. They establish a functional link
etween neural activity and local blood ﬂow.
.2. Oligodendrocytes and myelin sheath
Oligodendrocytes in the CNS wrap layers of specialized cell
embrane around neuronal axons to form the myelin sheath,
hich provides electrical insulation to increase axonal conduction
elocity and the speed of neural processing. Compacted myelin
rovides the high electrical resistance and low capacitance that
s essential for saltatory impulse propagation. Myelin contains
0%–80% lipids (by dry weight) but only a small set of proteins,
f which myelin basic protein (MBP) and proteolipid protein are
ost abundant (Simons and Nave, 2016). Moreover, myelin is
xtraordinarily stable as its lipid composition contains high levels
f saturated, long-chain fatty acids, together with an enrichment
f glycosphingolipids and cholesterol (Coetzee et al., 1996; O’Brien
nd Sampson, 1965). Myelin membrane has a high metabolic sta-
ility, as demonstrated in a recent study in which myelin proteins,
ogether with histones, nucleoporins, and lamins, were found to
e among the most long-lived proteins in the mouse (Toyama
t al., 2013). However, oligodendrocyte has high metabolic rate
nd the capacity to renew its myelin sheaths three times within
4 h. Indeed, a single oligodendrocyte provides multiple axons with
yelin sheaths (McTigue and Tripathi, 2008). As a consequence of
heir high metabolic rate, plus high intracellular iron stores andfrom Pereira and Furlan (2010) with authorization of the publisher. (For interpre-
tation of the references to colour in this ﬁgure legend, the reader is referred to the
web  version of this article.)
relatively low levels of anti-oxidative enzymes, oligodendrocytes
are extremely vulnerable to oxidative and endoplasmic reticulum
stress (Thorburne and Juurlink, 1996).
In a word, oligodendrocytes contact neurons by myelin sheath
which is stable in ultrastructure, chemical composition and
metabolic rate. However, oligodendrocyte per se has its high
metabolic rate and can rapidly renew its myelin sheaths.
2.3. Microglia
Microglia are resident immune cells of the CNS. They survey
the brain for damage and infection and have capacity of engulf-
ing dead cells and debris. Such functions are controlled by the
production of chemokines and cytokines, as well as by the pro-
duction of free radicals such as reactive oxygen species and nitric
oxide (Nimmerjahn et al., 2005; Saijo and Glass, 2011). In such
a microglia activation environment, oligodendrocytes are partic-
ularly susceptible to these microglia-derived factors because of
their high metabolic activity and energy demands. As a result of
oligodendrocyte damage/death, myelin impairment and demyeli-
nation may  occur as observed in neurological diseases. For example,
the endotoxin lipopolysaccharide (LPS) injected into the brain was
shown to invoke activation of astrocytes and microglia and the sub-
sequent production of a range of proinﬂammatory cytokines that
ultimately led to hypomyelination (Chew et al., 2013; Pang et al.,
2003). Moreover, in vitro microglia activation with LPS arrested
oligodendrocyte precursor cells (OPC) proliferation and induced
OPC death (Li et al., 2008; Sherwin and Fern, 2005). In addi-
tion, microglia have also been implicated in synaptic remodeling
during the development of the nervous system; in this process
microglia were proposed to remove inappropriate synaptic con-
nections through the process of phagocytosis (Ekdahl, 2012).
3. The neurochemical proﬁle detected by 1H MRS  in the
brain
At high magnetic ﬁeld [7 T and above], a neurochemical pro-
ﬁle of more than 20 metabolites can be determined under normal
physiological conditions (Fig. 3). Generally, 1H MRS  can detect all
compounds existing in a concentration above 0.5 mol/g (Duarte
et al., 2012b). These metabolites can be categorized into neu-
rotransmitters, energy metabolism, myelination and membrane
metabolism, antioxidants and osmolytes as well.
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.1. Neurotransmitters
The neurotransmitters detected by 1H MRS  include glutamate,
lutamine, GABA, N-acetylaspartylglutamate (NAAG), aspartate,
lycine, and serine. Glutamate and aspartate are the dominant
xcitatory amino acids. Glutamate does not generate a prominent
ingle peak in the 1H MRS  spectrum of the brain. A multiplet peak
entered at about 2.34 ppm arises from the methylene protons
nd is often the most readily recognized glutamate peak in brain
H MRS  spectra. A second methylene multiplet centered at about
.08 ppm is typically obscured by the large NAA peak at 2.01 ppm.
 third complex glutamate peak arises from its methine proton
t about 3.74 ppm (Govindaraju et al., 2000). These signals from
lutamate are difﬁcult to distinguish from the analogous peaks
rising from glutamine at about 2.44, 2.12, and 3.75 ppm. Unless
ptimized 1H MRS  methods are used (e.g. a high-ﬁeld scanner with
 short echo time and long acquisition time, or a specialized J-
diting or J-resolved sequence), the measurements obtained are
enerally considered to reﬂect the combined signal from glutamate
nd glutamine, with minor contributions from glutathione (GSH)
nd GABA. This combined signal measurement is often abbreviated
s “Glx.”
GABA is the most abundant inhibitory neurotransmitter in the
rain. It contains three methylene groups, each of which gives rise
o a complex signal in 1H MRS  spectra. The GABA multiplet peakm the rat hippocampus at 14.1 T using SPECIAL. Figure was reproduced from Duarte
at about 3.01 ppm is normally obscured by the creatine (Cr) singlet
at 3.03 ppm. The GABA triplet at about 2.28 ppm is partially over-
lapped by the glutamate multiplet centered at about 2.34 ppm. The
GABA multiplet peak at 1.89 ppm is obscured by the large NAA sin-
glet centered at 2.01 ppm. Because of their extensive overlap with
larger signals from other metabolites, none of the three GABA peaks
can be reliably distinguished or quantiﬁed with conventional brain
1H MRS  acquisitions at 1.5 or 3.0 T ﬁeld strengths (Maddock and
Buonocore, 2012).
NAAG is the most highly concentrated peptide in the human
brain (Neale et al., 2000). It generates a small peak in the brain 1H
MRS  spectrum that is difﬁcult to distinguish from the NAA peak
(Edden et al., 2007). Measures of the percent contribution of NAAG
to the combined signal from NAA and NAAG range from about 9%
in gray matter to about 30% in white matter (Edden et al., 2007;
Pouwels and Frahm, 1997).
The proton resonances of glycine are a singlet overlapping with
a more intense resonance of myo-inositol. This singlet has been
detected in brains of both rodents (Gambarota et al., 2008; Xin
et al., 2010) and humans (Gambarota et al., 2009). The coupled
proton spins of the methylene and methine groups of serine yield
resonances at 3.98, 3.94, and 3.83 ppm. The second one overlaps
with the prominent resonance of Cr at 3.91 ppm (Govindaraju et al.,
2000). The in vivo concentration of serine in the brain is very low
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around 0.4 mol) thus making quantiﬁcation of it with 1H MRS
ery difﬁcult.
.2. Energy metabolism
This category of brain metabolites involve glucose, lactate, ala-
ine, phosphocreatine (PCr) and Cr. Glucose is a major fuel for
rain energy production in the form of ATP molecules. The neuronal
ctivity and brain function depend on a continuous supply of glu-
ose through blood circulation and the speciﬁc glucose transport
echanism. The resonances of glucose between 3.2 and 3.9 ppm
re difﬁcult to be measured in 1H MRS  due to spectral overlap
ith peaks from more concentrated metabolites. The resonance of
lpha-d-glucose at 5.23 ppm may  overlap with the intense water
ignal at 4.72 ppm. Fortunately, this overlap was resolved in a study
y Gruetter et al. (1996), who demonstrated that the increased res-
lution at 4 T permiting to suppress the water signal sufﬁciently to
eliably detect glucose directly at 5.23 ppm by 1H MRS. In recent
nimal studies (Du et al., 2012; Duarte and Gruetter, 2012), the rat
rain glucose resonance peak at about 5.2 ppm was  detectable and
esolved at 9.4 T.
Lactate is the end product of glycolysis. Under normal circum-
tances, lactate is present only in minute amounts in the brain and is
ot resolved using the normal spectroscopic techniques. However,
t can be elevated in the brain under the conditions of ischemic
nd neuroinﬂammation (Ettl et al., 1994). Lactate is a doublet at
.3 ppm, which varies with different echo time (TE). At very short
r very long TE (30 or 288 ms), the doublet peak projects above the
aseline whereas it is inverted below the baseline on acquisitions
sing intermediate TEs (135/144 ms)  (Kwock, 1998). Alanine is an
mino acid with close links to metabolic pathways such as glycol-
sis, tricarboxylic acid (TCA) cycle and protein synthesis. It is also a
oublet peak at 1.48 ppm which may  be overshadowed by lactate.
The central peak on the spectrum at 3.02 ppm represents the
um of Cr and PCr. In the clinical setting, Cr is assumed to be stable
nd is used for calculating metabolite ratios (Cho/Cr and NAA/Cr
atios) (Danielsen et al., 1995). Caution is advised, however, as in
ases where there is tissue destruction, the level of Cr decreased,
s evidenced by decreased levels of Cr + PCr in brains of mice with
emyelination following exposure to cuprizone (a copper chelator)
or 6 weeks (Yan et al., 2015). Continually decreased levels of PCr
re suggestive of hypometabolism, possibly due to mitochondrial
ysfunction (Modica-Napolitano and Renshaw, 2004).
.3. Myelination and membrane metabolism
This type of brain metabolites involve phosphorylethanolamine
PE), phosphorylcholine (PC), glycerylphosphorylcholine (GPC),
nd NAA. The methyl protons of choline-compounds all resonate at
.2 ppm. In the brain, however, the main contributors to this peak
re PC and GPC as Choline (Cho) is below the NMR  detection limit
Klein, 2000). Therefore, the measured choline-compounds likely
eﬂect membrane lipid synthesis rather than the biosynthesis of
he neurotransmitter acetylcholine. Indeed, total Cho concentra-
ion (tCho) in the human brain is positively correlated with age,
hich has been attributed to increased release of water-soluble
holine-compounds from cell membranes, reﬂecting higher mem-
rane turnover (Duarte and Gruetter, 2012). PE is a precursor for
hosphatidylethanolamine, which is a major phospholipid in the
rain. In contrast to tCho, PE levels in the hippocampus, cortex, and
triatum of mouse decreased during adulthood and aging (Duarte
t al., 2014).
NAA is among the most abundant neurochemicals and taken
s a putative neuronal marker as it exclusively locates in neurons.
he highest peak in the normal spectrum resonating at 2.02 ppmioral Reviews 71 (2016) 563–577 567
represents NAA. With good resolution, the second and third peaks
of NAA can be observed at 2.6 and 2.5 ppm (Duarte et al., 2012b).
3.4. Antioxidants and osmolytes
Antioxidants and osmolytes that can be detected in the brain by
1H MRS  include GSH, vitamin C, taurine, myo-inositol and scyllo-
inositol. GSH and vitamin C are two major antioxidants that can be
detected by 1H MRS  using selective editing techniques (An et al.,
2009; Kaiser et al., 2010). Using MEGA-PRESS, only the 2.95 ppm
multiplet of GSH is observable and quantiﬁable whereas with point
resolved spectroscopy or the stimulated echo acquisition mode
localization, the entire GSH spectrum is quantiﬁed (Wijtenburg
et al., 2015). GSH acts in concert with vitamin C although they
are different in their locations: the former is more concentrated
in glia than neurons (Dringen, 2000) whereas the latter is pre-
dominantly in the neuronal compartment (Rice, 2000). Taurine
and myo-inositol are two osmolytes synthetized by astrocytes or
present in astrocytes. The resonance of myo-inositol is predomi-
nantly located at 3.56 ppm. This simple sugar is considered a glial
marker as it is primarily synthesized in glial cells, but is absent
from neurons (Castillo et al., 1998). Scyllo-inositol is the second
most concentrated isomer of inositol. It possesses six symmetric
protons and originates a singlet at 3.34 ppm (Duarte et al., 2012b).
4. The neurochemical correlate of neuron-astrocyte
integrity
The processes of astrocytes intimately contact neuronal cell
bodies and synapses. Astrocytes communicate with neurons via
a number of neurochemicals, of which glutamate, glutamine, and
the glutamate-glutamine cycle has been extensively studied and
documented well.
4.1. Glutamate-glutamine cycle relates to neuron-astrocyte
integrity
Glutamate and glutamine are compartmentalized in neurons
and glia, respectively. They can be converted into one another,
and this chemical inter-conversion reﬂects an important aspect of
metabolic interaction between these two types of neural cells. After
release into the synaptic cleft, glutamate is taken up by adjoining
neurons and astrocytes through the excitatory amino acid trans-
porters. Literally, astrocytes are responsible for uptake of most
extracellular glutamate via the high-afﬁnity glutamate transporters
GLT1 and GLAST. Via this mechanism, astrocytes are able to pre-
serve the extracellular concentration of glutamate at low levels thus
preventing excitotoxicity and keeping proper receptor-mediated
functions (Schousboe, 2003; Schousboe and Waagepetersen, 2005).
Once taken up into the astrocytes, glutamate is rapidly converted to
glutamine by the astrocyte-speciﬁc enzyme glutamine synthetase
(GS) that is largely restricted to this cell type. Small quantities of
glutamine are also produced de novo or from GABA (Bak et al.,
2006; Hertz and Zielke, 2004). Astrocytes release glutamine into
extracellular space where it can be taken up by glutamatergic
and GABAergic neurons. In glutamatergic neurons glutamine is
converted to glutamate by the neuron-speciﬁc enzyme phosphate-
activated glutaminase (Bak et al., 2006). Altogether these reactions
constitute the glutamate-glutamine cycle which is outlined in Fig. 4.
In GABAergic neurons, the reaction can go further and produce
GABA in the presence of glutamate decarboxylase thus extend-
ing the concept to the so-called glutamate-glutamine-GABA cycle
(Walls et al., 2015). However, only a small quantity of GABA is trans-
ported into astrocytes from the extra-synaptic space whereas most
of it is taken up by the presynaptic neurons (Schousboe et al., 2013).
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Fig. 4. Glutamate-glutamine cycle. After release into the synaptic cleft, glutamate is taken up by adjoining neurons and astrocytes through the excitatory amino acid trans-
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lutaminase. Figure was reproduced from Schousboe et al., 2013.
According to the above description, it is clear that the
lutamine/glutamate ratio in the brain is an index of glutamate-
lutamine cycle thus can be considered as the neurochemical
orrelate of neuron-astrocyte integrity. This ratio must be kept in
ertain range for a speciﬁc brain region. Abnormality of this ratio
an be determined by comparing values of this ratio between a
atient group and healthy subjects as demonstrated in human stud-
es with 1H MRS  (reviewed later). Changes of this index in either
irection can be suggestive of impairment in the neuron-astrocyte
ntegrity thus may  adversely affect brain functions. However, a
ormal glutamine/glutamate ratio does not necessarily indicate
he intactness of neuron-astrocyte integrity if changes in levels
f glutamine and glutamate are at a same direction and in same
roportions. Additionally, the glutamate-glutamine cycle may  be
odiﬁed by GABAergic transmission via a compensatory mech-
nism as evidenced by increased GABA levels in the pons and
utamen of early PD patients in the absence of other neurochemcial
odiﬁcations (Emir et al., 2012).
.2. Experimental evidence for impairment in neuron-astrocyte
ntegrityIn an animal model of schizophrenia, repeated injections of
K801 increased amounts of glutamate in frontal, retrosplenial,
nd cingulate cortices of rats, while the treatment induced hyper-
ocomotion, ataxia, abducted hind limbs, ﬂat body posture, andy the astrocyte-speciﬁc enzyme GS. Astrocytes release glutamine into extracellular
rgic neurons glutamine is converted to glutamate by the neuron-speciﬁc enzyme
stereotyped behavior. These results mimicked the results seen in
ﬁrst episode schizophrenic patients (Kondziella et al., 2006). In
another animal study, a neurotoxic amphetamine regimen (a sin-
gle dose of 30 mg/kg, i. p.) increased both glutamine content and
glutamine/glutamate ratio at 4 h, but not at 24 h, in all exam-
ined brain regions of the rat (caudate putamen, frontal cortex,
and hippocampus) after injection. According to the authors, ele-
vated glutamine levels and glutamine/glutamate ratios in all the
studied brain regions of amphetamine-injected rats compared to
controls are potentially due to enhanced conversion of glutamate
to glutamine by GS in astrocytes, accompanied by a compensatory
glutamate synthesis (Pereira et al., 2008). This explanation implies
that the treatment initially insulted astrocytes since the compen-
satory reaction happened in neurons. That is to say, the primary
cause of the neurobiological and behavioral changes in this animal
model is astrocyte impairment rather than neuronal dysfunction.
By employing 1H MRS  technique, we examined neuron-
astrocyte integrity in animals manipulated with other paradigms
applied in biological psychiatry research. In one study, rats were
socially isolated (1 rat/cage) for 8 weeks after weaning. The social
isolation (SI) was found to decrease levels of glutamate and glu-
tamine in the dorsal hippocampus while it led to a high level
of anxiety, social interaction deﬁcit and spatial working memory
impairment (Shao et al., 2015). The simultaneous decreases in glu-
tamine and glutamate suggest that both neurons and astrocytes
were insulted by SI for 8 weeks. In support of this explanation, the SI
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lso decreased levels of NAA and PCr in the same brain region, indi-
ating functional impairments in mitochondria of brain cells. These
hanges were accompanied by decreased activities of antioxidant
nzymes including catalase, glutathione peroxidase, superoxide
ismutase and total antioxidant capacity, as well as increased levels
f hydrogen peroxide, suggesting the existence of oxidative stress
fter SI for 8 weeks. Taken together, a delineation of the underly-
ng mechanism would be: chronic SI, by decreasing the antioxidant
apacity of neural tissue, induced the production of reactive oxygen
pecies (ROS) which inhibited mitochondrial oxidative metabolism
hus interrupted mitochondrial energy production (decreased PCr)
nd impaired neuronal viability (decreased NAA) and neuron-glial
ntegrity (decreased glutamate and glutamine). (Shao et al., 2015).
n line with this interpretation, abnormal redox homeostasis and
xidative stress have been proposed to play a role in the etiology
f several psychiatric disorders. At least in subgroups of patients,
xidative stress and altered anti-oxidant systems have been con-
idered a hallmark of schizophrenia (Do et al., 2009; Flatow et al.,
013; Fournier et al., 2014; Yao and Keshavan, 2011).
In a more recent study, adolescent Balb/c mice were subjected
o intermittent social defeat stress during postnatal days 28 to
2. This manipulation resulted in hypoactivity and social avoid-
nce which lasted into the early adulthood. Furthermore, it led
o transient decreases in levels of total creatine (tCr) and Glx
nd a delayed increase of NAA in the medial prefrontal cortex of
ice (Zhang et al., 2016). These neurochemical changes suggest
hat intermittent social defeat stress during early adolescence, like
I, insulted functions of both neurons and astrocytes, as well as
euron-astrocyte integrity. These impairments are associated with
he emotion-related behavioral alterations. Taken together, all the
ited animal studies by us and the other investigators demon-
trated that neuron-astrocyte integrity in the brain is vulnerable to
sycho-stimulants and psychological stressors, both of which are
isk factors for the development of psychopathology in humans.
. The neurochemical correlate of axon-myelin integrity
Communication between neurons and oligodendrocytes is
ccomplished through axon and myelin sheath. For example, high-
requency axonal ﬁring causes phosphorylation of MBP  in the white
atter tract of the hippocampus (Atkins et al., 1999). On the other
and, rapid impulse conduction depends on myelin sheath around
xons. The signals regulating the development and maintenance
f this exquisite neuron-oligodendroglial organization have been
 matter of intense research (Fields and Stevens-Graham, 2002).
owever, the interest of the authors here is to correlate axon-
yelin integrity to NAA involved in myelination and membrane
etabolism.
.1. NAA involves in myelination and axon-glial signaling
NAA is synthesized from acetyl coenzyme A and aspartate in
eurons by the mitochondrial enzyme NAA synthase in neurons
Baslow, 2000); whereas its degradation is majorly carried out by
ligodendrocyte-located aspartoacylase (ASPA) (Nordengen et al.,
015). In some neurons a portion of NAA is converted into NAAG
rom NAA and glutamate (Baslow, 2000). Levels of NAA in the brain
epend on both NAA synthase in neurons and ASPA in oligoden-
rocytes; the former increases, but the latter decreases levels of
AA (Fig. 5). On the basis of this, it is rational to consider NAA
he neurochemical correlate of neuron-oligodendrocyte or axon-
yelin integrity. Additional supports to this correlating are the
emonstrations of 1) NAA hydrolysis product acetate is required
or myelin lipid synthesis and loss of ASPA causes a reduction of
cetyl group supply for lipid synthesis (Chakraborty et al., 2001;ioral Reviews 71 (2016) 563–577 569
Namboodiri et al., 2006), and 2) accumulation of NAA to toxic lev-
els is the key event in the development of Canavan disease (CD), a
rare leukodystrophy caused by ASPA deﬁciency (Maier et al., 2015).
No abnormality of neurons has been reported in this disorder. Now
it is commonly accepted that NAA is involved in myelination and
axon-glial signaling, in addition to a role in osmoregulation (Moffett
et al., 2007).
5.2. NAA is being used as an index of axon-myelin integrity
In recent years, we measured levels of neurometabolites
in brains of mice by means of 1H MRS  and correlated NAA
to axon-myelin integrity in the brain. We  took advantage of
the cuprizone-fed mouse as an animal model of demyelina-
tion. C57BL/6 mice were fed cuprizone-containing diet for 6
weeks, which was  shown to selectively induce demyelination and
oligodendrocyte loss in previous studies (Xu et al., 2009; Yang
et al., 2009). The cuprizone-exposure increased anxiety levels and
impaired spatial working memory. Moreover, it decreased lev-
els of NAA and NAAG (Xuan et al., 2014, 2015; Yan et al., 2015).
These neurochemical changes were ascribed to the toxic effects
of cuprizone on mitochondria of brain cells as NAA is associ-
ated with mitochondrial function and oxidative stress (Marenco
et al., 2006). Indeed, a concurrent decrease in tCr was found in
the same brain region of these cuprizone-fed mice, indicating the
existence of impaired energy production from mitochondria (Yan
et al., 2015). These results suggest that cuprizone decreased NAA
levels by inhibiting energy production from mitochondria. This
mitochondrial impairment is fatal to oligodendrocytes thus dam-
ages axon-myelin integrity as these cells have high metabolic rate
and high intracellular iron stores but relatively low levels of anti-
oxidative enzymes (Thorburne and Juurlink, 1996).
Also, impairment in axon-myelin integrity may  be indicated by
higher levels of NAA. Evidence supporting this notion came from
a recent study from our group in which adolescent Balb/c mice
were subjected to intermittent social defeat stress for two weeks
during postnatal days 28 to 42. Interestingly, NAA levels in the
medial prefrontal cortex of mice showed no change one day after
the last defeat stress, but signiﬁcantly increased after a three-week
recovery period. And the NAA increase was concurrent with an
impeded myelination as evidenced by reduced MBP  immunoreac-
tivity (Zhang et al., 2016). Certainly, the normal NAA level detected
at the ﬁrst MRS  scanning may  be due to impairments in both neu-
rons and oligodendrocytes, instead of being an index of intactness
of these two  type of cells. There must be a decrease in NAA syn-
thesis due to neuronal impairment and a concurrent elevation of
NAA due to impaired ASPA in oligodendrocytes. This pair of coun-
teractions resulted in the outcome of no change in NAA level. After
a three-week recovery period, affected neurons recovered as they
are relatively resistant to the detriment whereas damaged oligo-
dendrocytes/myelination process was  not normalized yet as shown
in this study. As the result of this unparallel recovery, the defeated
mice showed a delayed increase in NAA level at the second MRS
scanning. This is similar to the situation in CD patients featured
with high levels of NAA and hypomyelination in the brain (Maier
et al., 2015).
In summary, both decrease and increase in NAA in the brain are
suggestive of impairment in the axon-myelin integrity. Increased
NAA results from reduced ASPA in oligodendrocytes thus can be
suggestive of an oligodendrocyte impairment as in CD and the
aforementioned our recent study. Also in this case oligodendrocytes
may  have reduced NAA catabolism to satisfy efﬁcient myelination.
Decreased NAA resulting from defective NAA synthesis in neuronal
mitochondria leads to insufﬁcient provision of NAA to oligodendro-
cytes and thus impairs myelination (Fig. 5).
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Fig. 5. NAA involves in myelination and axon-glial signaling. NAA is synthesized from acetyl coenzyme A and aspartate in neurons by the mitochondrial enzyme NAA
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nd  glutamate (not shown). Levels of NAA in the brain depend on both NAA syntha
or  myelin lipid synthesis and loss of ASPA causes a reduction of acetyl group suppl
. Neuron-glia integrity impairments in patients with
chizophrenia
Schizophrenia is the most devastating mental illness, affect-
ng 0.66% of the population at some point in their lifetime (Kasai
t al., 2002; Lewis and Lieberman, 2000; van Os and Kapur, 2009).
ymptoms of this mental disorder typically develop in late ado-
escence or early adulthood. The various symptoms afﬂicting the
atients are loosely clustered into four groups of the positive, nega-
ive, cognitive, and depressive symptoms. Although the exact cause
f schizophrenia remains to be elucidated, 1H MRS studies with
chizophrenia patients have provided a great body of neurochem-
cal data. Here we review some of them relevant to neuron-glia
ntegrity in patients with schizophrenia.
.1. Neuron-astrocyte integrity impairment in schizophrenia
atients
In the late 1990s, proton studies of postmortem schizophrenic
rains showed reduced glutamate (Omori et al., 1997). Prompted
y this study, Theberge et al. (2002, 2003) performed 1H MRS  stud-
es with two groups of patients with schizophrenia: ﬁrst-episode
ever-treated patients and chronic treated patients. They found
igh levels of glutamine in the left anterior cingulate and left tha-
amus of patients with ﬁrst-episode never-treated schizophrenia
ith respect to healthy controls at 4.0 T but signiﬁcantly reduced
lutamate and glutamine in the anterior cingulate cortex (ACC) of
hronically ill patients. In accordance with the high levels of glu-
amine in patients with ﬁrst-episode never-treated schizophrenia,
 study of non-psychotic adolescents at genetic risk for schizophre-
ia reported signiﬁcantly increased Glx in the right medial frontallocated ASPA. In some neurons a portion of NAA is converted into NAAG from NAA
eurons and ASPA in oligodendrocytes. NAA hydrolysis product acetate is required
ipid synthesis.
lobe (Tibbo et al., 2004). However, it was reported that glutamine
levels in the anterior cingulate and thalamus reduced as disease
progressed and this reduction correlated with progressive gray
matter loss in the same regions (Theberge et al., 2007). Simi-
larly, decreased Glx was found in the dorsolateral prefrontal cortex
(DLPFC) of patients with chronic illness with respect to ﬁrst-episode
medication naïve patients and healthy controls (Ohrmann et al.,
2005). Interestingly, a few other studies have found no differences
in Glx in the ACC in chronically ill medically stable patients (Ongur
et al., 2010; Reid et al., 2010; Wood et al., 2007). Moreover, a recent
study reported that the Glx level was  signiﬁcantly elevated in the
left inferior parietal white matter in the patients with psychotic
exacerbation in comparison with that in the healthy volunteers
and the patients without exacerbation, indicating the existence of
glutamatergic over-activity in this brain region (Ota et al., 2012).
Although the results of above cited studies seem to be mixed,
they are not in conﬂict with the neuron-astrocyte integrity the-
ory proposed in this article. According to this theory, astrocytes
are more likely to be insulted while protecting neurons in the
brain. If the damage is not severe and destructive, astrocytes in the
affected brain region may  produce more glutamine in comparison
with the normal condition as demonstrated in the amphetamine-
treated rats (a single dose of 30 mg/kg, i.p.) showing increased
glutamine and glutamine/glutamate ratio at 4th hour, but not at
24th hour, in all examined brain regions (Pereira et al., 2008). Fol-
lowing any damage to neurons, astrocytes become activated and
may  synthesize more glutamine. At the early stage, glutamate may
not decrease; but if the insult persists for a long period, glutamate,
glutamine, and Glx may  decrease. This explannation suggests that
the glutamine/glutamate ratio or Glx levels is a dynamic process,
instead of a ﬁxed point as in the older concept of homeostasis.
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ith the neuron-astrocyte integrity theory, we have no difﬁculty
n understanding the high levels of glutamine in the left anterior
ingulate and left thalamus of patients with ﬁrst-episode never-
reated schizophrenia and signiﬁcantly reduced glutamate and
lutamine in the ACC of chronically ill patients reported in pre-
ious human studies (Omori et al., 1997; Theberge et al., 2002,
003, 2007; Tibbo et al., 2004). More signiﬁcantly, this interpreta-
ion made sense of all data summarized in a recent meta-analysis
Marsman et al., 2013), including: 1) glutamate level (resulted
rom 9 studies with a total of 166 patients and 171 healthy con-
rols) in the medial frontal region was lower in schizophrenia
atients than in controls; 2) glutamine level (resulted from 8
tudies with a total of 140 patients and 135 healthy controls) in
he same region was higher in patients than in controls; 3) glu-
amine/glutamate ratio (resulted from 6 studies with a total of
12 patients and 116 healthy controls) in the region was higher in
atients than in controls but this was not signiﬁcant. Another two
ecent studies published after the above meta-analysis (Bustillo
t al., 2010; Shirayama et al., 2010) speciﬁcally measured the glu-
amine/glutamate ratio with high-ﬁeld scanners and both found
n elevated glutamine/glutamate ratio in the medial prefrontal
ortex or ACC of patients with schizophrenia. In a more recent
tudy (Bustillo et al., 2014), glutamine and glutamine/glutamate
atio were increased, but glutamate did not change, in schizophre-
ia patients who underwent long-term antipsychotic treatments.
aken together, an increased glutamine is likely to be an early stage
ndex of schizophrenia; whereas decreased glutamate with or with-
ut glutamine decrease is suggestive of neuronal impairment in
hronic schizophrenia patients. In both the early and late stages,
euron-astrocyte integrity is impaired.
While appreciating the usefulness of the neuron-astrocyte
ntegrity theory, which implicitly relates to the glutamatergic
ypothesis of schizophrenia, in explaining the mixed ﬁndings
rom human studies with schizophrenia patients, we  did not
ntentionally ignore the other approaches as the dopaminergic
nd serotoninergic ones. Indeed, glutamatergic and dopaminergic
ypotheses are not mutually exclusive as evidenced by ﬁndings
n humans and animals concluding that chronic dopamine deple-
ion (>4 months) decreases striatal glutamate levels whereas acute
lterations in striatal dopamine functioning, speciﬁcally at the D2
eceptors, may  produce opposite effects (Caravaggio et al., 2016).
.2. Axon-myelin integrity impairment in schizophrenia patients
Early 1H MRS  studies have reported reduced NAA in sev-
ral brain regions of patients with schizophrenia (Choe et al.,
994). Reduced NAA has also been reported in ACC of chronic
chizophrenia (Reid et al., 2010). Interestingly, reduced NAA lev-
ls were accompanied by decreased glutamate and myo-inositol
Chang et al., 2007). Moreover, signiﬁcant decreases in NAA, Cr,
nd Cho were also found in subjects with genetically high risk
f schizophrenia (Yoo et al., 2009). The concurrent decreases
n NAA and glutamate suggest the existence of damaged gluta-
atergic neurons and impaired neuron-oligodendrocyte integrity.
ecreased myo-inositol and Cho could be due to damage to or
mpairments in glia cells. On the other hand, concurrent increases
n glutamine/glutamate ratio, lactate, and NAA were seen in mouse
ith impaired GSH synthesis (Corcoba et al., 2016), suggesting
lterations in the glutamatergic neurotransmission system (Duarte
t al., 2012a) and in the metabolic coupling between neurons and
lia (Tranberg et al., 2004; Yang et al., 2014).
In the meta-analysis by Steen et al. (2005), a total of 1256
chizophrenia patients were compared to 1209 controls. The results
ndicated consistent decreases in NAA levels in the frontal lobe and
ippocampus. Following that, a recent meta-analysis reported sig-
iﬁcant reductions in NAA in various regions of the brain in chronicioral Reviews 71 (2016) 563–577 571
and ﬁrst-episode patients, but the NAA reductions did not reach the
signiﬁcant level in genetically at-risk patients (Brugger et al., 2011).
In a recent study published after the above meta-analysis, NAAG
was increased at a trend level in ACC of patients with schizophrenia,
while NAA was  reduced. The ratio NAAG/NAA was increased (Jessen
et al., 2013). In a more recent study, concurrent decreases in frontal
NAA and Glx were found in patients with chronic schizophrenia but
not in those at clinical high risk for psychosis or with ﬁrst-episode
schizophrenia (Natsubori et al., 2014). This ﬁnding is reminis-
cent of the tight connection between NAA and glutamate, in part
through TCA and glutamate-glutamine cycle (Moffett et al., 2007).
Indeed, a positive correlation between NAA/Cr and Glx/Cr in the
dorsal ACC, pregenual ACC, cerebellum, and hippocampus has been
demonstrated in healthy persons (Kraguljac et al., 2012b, 2013;
Waddell et al., 2011). But, this coupling is disrupted in patients
with schizophrenia (Coughlin et al., 2015; Kraguljac et al., 2012b).
In the most recent study, chronicity of schizophrenia was related
to decreased levels of Glx and NAA; whereas people at ultra-high
risk (UHR) for psychosis showed increased levels of prefrontal Glx
and NAA with increasing age (Liemburg et al., 2016). Although the
glutamate hypothesis of schizophrenia has no difﬁculty to explain
the concurrent decreases in glutamate and NAA in schizophrenia
patients, the neuron-glia integrity theory proposed here can inter-
pret both the concurrent decreases in NAA and glutamate in chronic
patients and increased levels of prefrontal Glx and NAA in people
at UHR for psychosis. Simply, high levels of NAA may  result from
oligodendroglia dysfunction; increased Glx may be suggestive of
astrocyte pathology as explained earlier.
7. Neuron-glia integrity impairments in patients with
bipolar disorders
BD is characterized by episodes of manic and depressed moods
interspersed with periods of relatively normal mood. Its life time
prevalence is approximately 4.4%, as ascertained by the National
Comorbidity Survey Replication study (Merikangas et al., 2007).
Although many studies have investigated the neurobiology of BD,
its underlying pathophysiology has yet to be elucidated (Kato,
2008). The task here is to review some of 1H MRS  studies with BD
patients from the point of neuron-glia integrity.
7.1. Neuron-astrocyte integrity impairment in patients with BD
To date, many 1H MRS  studies with BD patients have been
published, but results are mixed with respect to glutamate and
Glx. In some of previous 1H MRS  studies, increased glutamate lev-
els were found in various brain regions, including the occipital
cortex (Bhagwagar et al., 2007; Senaratne et al., 2009), the parieto-
occipital cortex (Ongur et al., 2008), the hippocampus (Colla et al.,
2009), the insula (Dager et al., 2004), the ACC (Frye et al., 2007;
Ongur et al., 2008), and the left DLPFC (Michael et al., 2009), of
patients with BD. In contrast, other studies reported decreased glu-
tamate levels in the frontal white matter bilaterally and the right
lentiform nucleus of BD patients (Port et al., 2008) or in the ACC of
pediatric offspring of parents with BD (Singh et al., 2010). On the
other hand, there are a number of studies that showed no differ-
ences in glutamate levels between BD patients and healthy controls
(Frey et al., 2007; Kaufman et al., 2009; Port et al., 2008; Senaratne
et al., 2009). A recent meta-analysis (Gigante et al., 2012) concluded
that Glx levels were higher in BD patients compared to healthy sub-
jects when all brain areas were combined. This ﬁnding remained
true in medicated and non-medicated patients, and in frontal brain
areas in adults. Elevated Glx in BD patients reﬂects an increase in
glutamatergic neurotransmission, at least in ACC (Soeiro-de-Souza
et al., 2013).
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Since Glx represents the sum of glutamate and glutamine sig-
als, the reported increase in Glx in previous studies could reﬂect
ncreased glutamate, increased glutamine, or even elevated lev-
ls of both of them. Indeed, Ongur and colleagues (Ongur et al.,
008) reported a higher ACC glutamine/glutamate ratio in 18 med-
cated manic BD patients compared to healthy controls, suggesting
n increased level of glutamine. Following that, Brennan et al.
eported an increased glutamine/glutamate ratio in BD depression
fter treatment with riluzole (Brennan et al., 2010). In a more recent
tudy, glutamine level was higher in euthymic BD patients than
n healthy controls. The glutamate level and glutamate/glutamine
atio were lower in BD patients than in controls. Interestingly,
he use of anticonvulsants was associated with glutamine increase
ut did not affect glutamate or glutamate/glutamine ratio. Nei-
her lithium nor antipsychotic use inﬂuenced metabolite levels
Soeiro-de-Souza et al., 2015). In another recent study, however,
lutamate concentrations were signiﬁcantly increased in the ACC,
ut decreased in the hippocampus of BD patients. And an inverse
orrelation was observed for glutamate concentrations in the ACC
nd number of episodes (Ehrlich et al., 2015). In conclusion, the
ost consistent ﬁnding in BD patients is the elevation of Glx in
CC, glutamate may  increase or decrease. The changes in other
rain regions are inconsistent. According to the neuron-astrocyte
ntegrity theory, either change in Glx, glutamate, glutamine, or glu-
amine/glutamate ratio, reﬂects glutamatergic dysfunction and/or
mpaired neuron-astrocyte integrity. Dependent on the disease sta-
us (the euphoric or depressed phase) and brain regions, these
ndices may  inrease or decrease.
While helping psychiatrists to explain inconsistent ﬁndings
rom human studies and understand important roles of glutamate-
lutamine cycle in the pathogenesis of BD, the neuron-astrocyte
ntegrity theory provides no details of how it is involved in
motional processes. Speciﬁcally, it does not encompass the
alcium-evoked release of messengers from astrocytes that has
een suggested to regulate the energy supply to the brain neu-
ons (Attwell et al., 2010). Other details include how glutamate
Schummers et al., 2008) and GABA transporters (Doengi et al.,
009) raise calcium ions in astrocytes; and how the modulatory
eurotransmitters noradrenaline (Duffy and MacVicar, 1995) and
ccetylcholine (Shelton and McCarthy, 2000) regulate astrocyte cal-
ium ions.
.2. Axon-myelin integrity impairment in patient with BD
In an earlier 1H MRS  study, Winsberg et al. reported that NAA/Cr-
Cr ratios in the DLPFC were lower on the right and left hemispheres
f BD patients compared with healthy controls (Winsberg et al.,
000). Shortly after that, Cecil et al. (2002) found reductions of NAA
nd Cho concentrations in both the gray matter medially and white
atter laterally within the frontal lobe of BD patients compared to
ealthy subjects. Although some of later studies could not observe
AA change in BD patients (Brambilla et al., 2005; Dager et al.,
004; Scherk et al., 2009), a number of 1H-MRS studies demon-
trated signiﬁcantly reduced NAA levels in their patient groups.
he brain regions examined include ACC (Patel et al., 2008), hip-
ocampus (Atmaca et al., 2006), DLPFC (Molina et al., 2007), and
asal ganglia (Frye et al., 2007). In a meta-analysis, which included
2 studies involving 328 adult bipolar and 349 control subjects,
ildiz-Yesiloglu and Ankerst (2006a) concluded that NAA levels
ere lower in euthymic bipolar patients in the frontal lobe struc-
ures and hippocampus. And lithium seems to have an increasing
ffect on NAA in those brain regions. There are data in children indi-
ating lower NAA levels in euthymic bipolar patients in DLPFC and
erebellar vermis. But, other investigators did not ﬁnd decreased
AA/Cr ratios in DLPFC of children and adolescents with BD (Gallelli
t al., 2005). Interestingly, a recent systemic review summarizedioral Reviews 71 (2016) 563–577
that decreased NAA levels in the basal ganglia were the most con-
sistent ﬁndings in BD; whereas NAA levels in the DLPFC increased
compared to healthy controls (Kraguljac et al., 2012a). Although
the ﬁnding of an increase in NAA appears counter-intuitive, it is not
conﬂict with the neuron-glia integrity impairment theory proposed
here. Literally, either decrease or increase in NAA is suggestive
of axon-myelin integrity impairment. Decreased NAA may  mainly
result from neuronal impairment; whereas increased NAA is due
to oligodendroglial deﬁcits as explained before.
8. Neuron-glia integrity impairments in patients with
major depressive disorder
MDD  has the highest worldwide morbidity among neuropsy-
chiatric disorders across all socioeconomic strata, with a lifetime
prevalence of 15–20% (Kessler et al., 2003; Ormel et al., 2008; Ustun,
2000). Patients with MDD  suffer episodes of sustained depressed
mood, loss of motivation, and the associated somatic, emotional,
and cognitive symptoms of depression. Although the neurobiology
of MDD  has not been clariﬁed, advances have been achieved due
to the applications of new techniques including positron emission
tomography (PET), MRI, and MRS  in clinical practice and research.
For example, there is consistent evidence for a volume reduction in
prefrontal regions, especially the orbital frontal cortex, the ACC, ros-
troventral terminus, and the subgenual cingulate cortex in patients
with MDD  (Hajek et al., 2008; Konarski et al., 2008; Savitz and
Drevets, 2009). Here we focus on 1H MRS  ﬁndings, especially those
relevant to neuron-astrocyte and axon-myelin contacts, in MDD
patients.
8.1. Neuron-astrocyte integrity impairment in patients with MDD
Earlier 1H MRS  studies with MDD  patient reported signiﬁ-
cantly lower Glx levels in frontal lobe structures (Auer et al.,
2000; Michael et al., 2003; Pﬂeiderer et al., 2003). A meta-analysis
over the three studies also found signiﬁcantly lower Glx levels in
frontal lobe structures in adult MDD  patients relative to healthy
controls (Yildiz-Yesiloglu and Ankerst, 2006b). In a later compre-
hensive review, Yuksel and Ongur (2010) identiﬁed 9 studies that
measured Glx levels in prefrontal or limbic regions in currently
depressed adult patients with MDD. 6 of the 9 studies reported sig-
niﬁcantly reduced Glx in prefrontal regions, the hippocampus and
the amygdala. They provided suggestive evidence for reduced glu-
tamine/glutamate ratio in depression patients. In another review
article, Kondo and colleagues (Kondo et al., 2011) reported a sim-
ilar consistent reduction in prefrontal Glx of major depression in
children and adolescents. In addition, decrease in glutamine was
also found in the ACC of ﬁve highly anhedonic patients with MDD
(Walter et al., 2009). Different from these previous studies, Taylor
et al. (2009) reported normal glutamate but elevated myo-inositol
in ACC in recovered depressed patients. Moreover, the same group
reported that participants with a parental history of depression had
signiﬁcantly higher levels of glutamate than controls in parieto-
occipital cortex (Taylor et al., 2011).
The mixed results from previous studies suggest that changes
in glutamatergic transmission may  be region and state speciﬁc in
MDD. In line with this suggestion, a recent meta-analysis detected
a consistent decrease in Glx and glutamate in the ACC of MDD
patients; but, Glx decrease in other brain regions was found only
during depressive episodes (Luykx et al., 2012). Further support to
this suggestion came from a recent study, in which levels of gluta-
mate were signiﬁcantly decreased in ventromedial prefrontal areas
including the rostral cingulate gyrus, and Broadmann’s areas 10, 24
and 32 of remitted-recurrent and chronic MDD  patients compared
with both ﬁrst-episode and controls. And level of glutamate was
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egatively correlated with illness duration (Portella et al., 2011).
nterestingly, a reduction in glutamate levels in occipital cortex was
orrelated with successful cognitive behavioral therapy and antide-
ressant medication response in MDD  patients. But, the authors did
ot compare glutamate level in MDD  patients to that in healthy
ontrols (Abdallah et al., 2014). In a more recent meta-analysis
Arnone et al., 2014), a comprehensive literature searching up to
014 identiﬁed 17 reports which measured absolute concentra-
ions of neurometabolites in the prefrontal cortex with 1H MRS. The
nalysis showed an exclusive reduction in absolute values of Glx in
he prefrontal cortex in depression; whereas glutamate measure-
ents in isolation did not differ vs healthy controls or in relation to
reatment and/or clinical improvement. The authors concluded that
he reduction in the absolute Glx values in the absence of changes in
lutamate levels suggests a possible modulatory role of astrocytes
n the pathophysiology of depression. This conclusion is in line with
ur theory that the neuron-astrocyte integrity in MDD  patients is
amaged.
.2. Axon-myelin integrity impairment in patients with MDD
Although 1H MRS  has been used to study MDD, results and con-
lusions are different across published studies with respect to data
f indices relevant to axon-myelin integrity. Reviews and meta-
nalyses of the 1H MRS  literature on MDD  through 2006 found no
onsistent evidence that NAA was either increased or decreased in
dult or pediatric patients with major depression (Capizzano et al.,
007; Kondo et al., 2011; Yildiz-Yesiloglu and Ankerst, 2006b).
f the studies that were published after 2006, the vast majority
eported reduced NAA in recurrent and chronic patients as well as
ate-life depression. The examined brain regions include the pre-
rontal cortex (Portella et al., 2011; Venkatraman et al., 2009; Zhong
t al., 2014), the frontal white matter (Chen et al., 2009; Jia et al.,
015; Wang et al., 2012), and the cingulum (Merkl et al., 2011). But,
o changes were found in ﬁrst episode major depression (Kaymak
t al., 2009; Portella et al., 2011) and mild MDD  patients (Sozeri-
arma et al., 2013).
Interestingly, older previously depressed individuals showed
igniﬁcantly elevated left medial temporal lobe concentrations of
AA and myo-inositol while they showed signiﬁcantly reduced
oncentrations of NAA, Cho, and Cr in the prefrontal cortex, indicat-
ng a region speciﬁc feature of the neurochemical changes in MDD
Venkatraman et al., 2009). Higher myo-inositol/tCr ratios were
lso seen in the basal ganglia in another study (Chen et al., 2009).
oreover, Cho (in the ventromedial prefrontal region) presented
he lowest levels in ﬁrst-episode patients and healthy controls,
ut the highest values in remitted-recurrent and chronic patients.
nd the tendency of progressive changes of glutamate and Cho
etabolites was clearly related to illness duration regardless the
tate of mood at scanning time (Portella et al., 2011). According
o the authors, abnormalities in myelination and/or glial function
long the course of the illness may  underlie the augmented Cho
oncentrations observed in this brain region. Increased Cho levels
ay  also reﬂect neuronal membrane breakdown and/or alterations
n cellular signal transduction systems in the prefrontal cortex
aused by past illness burden (Portella et al., 2011). The latter
xplanation is in line with a previous study reporting Cho to be
igniﬁcantly increased in the hippocampus of patients with exten-
ive past illness (Milne et al., 2009). Different from these previous
tudies, a recent study reported that the bilateral ventral prefrontal
hite matter of MDD  patients showed signiﬁcantly lower Cho/Cr
t the baseline (before receiving treatment). But, the values of post-
reatment patients were increased signiﬁcantly compared to that
f pre-treatment (Zhang et al., 2015). Lower ratio of Cho/Cr was
lso considered to be suggestive of abnormalities in membrane
tructure and function of glial cells and myelin, as exempliﬁedioral Reviews 71 (2016) 563–577 573
by the association between reduction of Cho levels and decreased
membrane turnover (Glitz et al., 2002). In conclusion, concurrent
changes of NAA and Cho or myo-inositol in either direction are solid
evidence for damage to neuron-oligodendrocyte or axon-myelin
integrity in MDD. NAA and choline-containing neurochemicals are
relevant to myelination and membrane metabolism while myo-
inositol is considered a glial marker as reviewed earlier.
9. Different 1H MRS  ﬁndings in neurodegenerative diseases
than mental disorders
For experienced neurologists and psychiatrists, differentiating
mental disorders from neurodegenerative diseases is not a difﬁ-
cult task. Signiﬁcantly these two types of brain diseases are also
different in 1H MRS  ﬁndings. In a recent review, Duarte and col-
leagues summarized main metabolic changes in neurodegenerative
disorders measured by 1H MRS. All three neurodegenerative disor-
ders of Alzheimer’s disease (AD), Huntington’s disease (HD), and
Parkinson’s disease (PD) presented decreased NAA but increased
glutamine and lactate. Both AD and HD showed higher levels of
myo-inositol (Duarte et al., 2013). Decreased NAA and increased
lactate are consistent with neuronal loss and mitochondrial dys-
function, a common characteristic of all these three diseases.
Increased glutamine concurrent with changed glutamate suggest
the existence of an impaired glutamatergic neurotransmission.
Higher levels of myo-inositol are indicative of astrogliosis in
response to neuronal pathology. Taken together, these consistent
changes in 1H MRS  suggest that brain neuron is the damaged or
destroyed party in these neurodegenerative diseases. In contrast,
there is no consistent 1H MRS  changes in mental disorders as
reviewed in this article. According to the neuron-glia integrity the-
ory, the pathology of these disorders starts on neuron-glia contacts.
In late stages, brain neurons may  become the main victim indicated
by decreased brain levels of NAA, glutamate, and GABA.
10. Concluding remarks
Although exceedingly complex, neural cells can be divided into
two functionally different types: the electrically excitable neurons
and electrically non-excitable glia. Astrocytes regulate synaptic
transmission between neurons as the third part of the tripar-
tite synapse. They communicate each other through waves of
calcium ions propagating information over large distances. Oligo-
dendrocytes contact neurons by myelin sheath which is stable in
ultrastructure, chemical composition and metabolic rate. However,
oligodendrocyte per se has its high metabolic rate and can rapidly
renew its myelin sheaths.
The glia cells not only contact neurons physically but also
communicate with neurons chemically. Chemicals important to
brain function fall under numerous classiﬁcations including gases,
molecules signiﬁcant to energy, classical neurotransmitters, and
bioactive proteins. Of the existing detecting/analyzing methods,
the 1H MRS  measures the abundance of neurochemicals hence
can probe disorder phenotypes at clinical and sub-clinical lev-
els. The glutamine/glutamate ratio in the brain is an index of
glutamate-glutamine cycle thus can be considered the neurochem-
ical correlate of neuron-astrocyte integrity. NAA levels rely on the
normal functions of both neurons and oligodendrocytes. Therefore,
NAA is considered to be the neurochemical correlate of neuron-
oligodendrocyte or axon-myelin integrity.
According to the proposed neuron-astrocyte integrity theory,
either change in Glx, glutamate, glutamine, or glutamine/glutamate
ratio, reﬂects glutamatergic dysfunction and/or altered astrocytes,
indicating impairment in the neuron-astrocyte integrity. Higher
levels of Glx indicates the existence of glutamatergic overactiv-
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ty, with higher glutamate indicating a neuronal compensatory
eaction in response to overproduction of glutamine in astrocytes.
ower glutamate indicates functional deﬁcit of glutamatergic neu-
ons which may  be accompanied with increased or decreased
lutamine. According to the neuron-oligodendrocyte integrity the-
ry, decreased NAA mainly results from mitochondrial dysfunction
f neurons; whereas increased NAA is due to oligodendroglial
eﬁcits. Concurrent changes in NAA and Cho/myo-inositol in either
irection are solid evidence for damage to neuron-oligodendrocyte
r axon-myelin integrity. Upon these two theories, neurochemical
hanges detected by 1H MRS  in brains of patients with psychiatric
isorders including schizophrenia, BD, and MDD  provided com-
elling evidence for impairments in neuron-glia integrity, although
hese impairments are region- and state-speciﬁc in individual
atient.
The neuron-glia integrity theory can be further extended in
uture human studies to follow up the disease progress and explore
he neurobiological substrates of extant and new medical and psy-
hological avenues for the treatment of psychiatric disorders. It
ay  inspire future basic and clinical studies to investigate impor-
ant roles of impaired neuron-glia integrity in the pathogenesis and
reatment of psychiatric disorders. With advances in spectroscopic
maging and the chemical exchange saturation transfer methods
or mapping brain metabolite changes, future studies are expected
o detect and compare 1H MRS  change proﬁles of various mental
isorders and at differnet stages of a same disorder so as to clarify
 diagnosis or determine the stage of a mental disorder. Treating
mpaired neuron-glia integrity will be a new strategy for treating
sychiatric disorders at least in the early stage of a mental disorder
hen the neurons are not damaged yet.
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